Cited by 109Pharmaceutical industry and healthcareInflammatory mediators and NSAID effectsPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Expression of Concern Reaffirmed

Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M.·2006·New England Journal of Medicine

DOI 10.1056/nejme068054

Open this paper in CoChat — free account

Abstract

On December 8, 2005, we published an expression of concern1 regarding an article by Bombardier et al. on the Vioxx Gastrointestinal Outcomes Research (VIGOR) study that was published in the Journal on November 23, 2000.2 Our expression of concern was prompted by evidence that the VIGOR article did not accurately represent the safety data available to the authors when the article was being reviewed for publication. More than four months before the article was published, at least two of its authors were aware of critical data on an array of adverse cardiovascular events that were not included in the VIGOR . . .

Integrity signals

Registry

Crossref · 10.1056/nejme068054

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS
Ombardier, C. L. B., Aine, L. O. L., Eicin, A. L. R., Hapiro, D. E. S., Urgos, R. U. B., Avis, B. A. D., Ay, R., Arcos, M. J., Erraz, B. O. F., Awkey, C. H. J. H., et al. (2010) · Cited by 252
Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8.
Curfman, G., Morrissey, S., & Drazen, J. M. (2005) · New England Journal of Medicine · doi:10.1056/nejme058314 · Cited by 157
Self-citation
Response to Expression of Concern Regarding VIGOR Study
Bombardier, C., Laine, L., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., Schnitzer, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc066096 · Cited by 29

Show all 4 references

Research works printed but not linked: 2

Reicin A, 2006, N Engl J Med, 354, 1198
10.1056/NEJMe058314 · DOI

Sorted by citations

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Jüni, P. (2011) · BMJ · doi:10.1136/bmj.c7086 · Cited by 1,196
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis
Ford, A. C., Talley, N. J., Spiegel, B. M. R., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M. M., & Moayyedi, P. (2008) · BMJ · doi:10.1136/bmj.a2313 · Cited by 565
Publication Bias in the Organizational Sciences
Kepes, S., Banks, G. C., McDaniel, M. A., & Whetzel, D. L. (2012) · Organizational Research Methods · doi:10.1177/1094428112452760 · Cited by 416
A Comprehensive Survey of Retracted Articles from the Scholarly Literature
Grieneisen, M. L., & Zhang, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044118 · Cited by 355
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 331
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.306 · Cited by 287
Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga
Großer, T., Yu, Y., & FitzGerald, G. A. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-011209-153129 · Cited by 232
Reproducible Research: Moving toward Research the Public Can Really Trust
Laine, C., Goodman, S. N., Griswold, M. E., & Sox, H. C. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-6-200703200-00154 · Cited by 213
Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols
Chan, A.-W., Hrobjartsson, A., Jorgensen, K. J., Gotzsche, P. C., & Altman, D. G. (2008) · BMJ · doi:10.1136/bmj.a2299 · Cited by 202
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials
Stiller, C., & Hjemdahl, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13505 · Cited by 207
Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the Working Group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv505 · Cited by 164
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results
Chan, A.-W. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050230 · Cited by 144
Why we need easy access to all data from all clinical trials and how to accomplish it
Gøtzsche, P. C. (2011) · Trials · doi:10.1186/1745-6215-12-249 · Cited by 137
Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles
Tang, E., Ravaud, P., Riveros, C., Perrodeau, É., & Dechartres, A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0430-4 · Cited by 137
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
Becker, M. C., Wang, T. H., Wisniewski, L., Wolski, K., Libby, P., Lüscher, T. F., BORER, J. S., Mascette, A. M., Husni, M. E., Solomon, D. H., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.12.014 · Cited by 124
Avoiding Bias in Publication Bias Research: The Value of “Null” Findings
Kepes, S., Banks, G. C., & Oh, I. (2012) · Journal of Business and Psychology · doi:10.1007/s10869-012-9279-0 · Cited by 132
Pharmaceutical Controversies and the Performative Value of Uncertainty
McGoey, L. (2009) · Science as Culture · doi:10.1080/09505430902885474 · Cited by 99
Lessons from the Vioxx Debacle: What the Privatization of Science Can Teach Us About Social Epistemology
Biddle, J. B. (2007) · Social Epistemology · doi:10.1080/02691720601125472 · Cited by 105
Evidence-Based Decision Making: When Should We Wait For More Information?
Chalkidou, K., Lord, J. L., Fischer, A., & Littlejohns, P. (2008) · Health Affairs · doi:10.1377/hlthaff.27.6.1642 · Cited by 78
Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis
Schroll, J. B., Penninga, E. I., & Gøtzsche, P. C. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002101 · Cited by 69
The Influence of Money on Medical Science
DeAngelis, C. D. (2006) · JAMA · doi:10.1001/jama.296.8.jed60051 · Cited by 69
NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies
García Rodríguez, L. A., González-Pérez, A., Bueno, H., & Hwa, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016780 · Cited by 59
The pharmacology of selective inhibition of COX-2
Großer, T. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-08-0444 · Cited by 60
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis
He, L., Fang, H., Chen, C., Wu, Y., Wang, Y., Ge, H., Wang, L., Wan, Y., & He, H. (2020) · Medicine · doi:10.1097/md.0000000000019760 · Cited by 55
Comparison of Randomized Controlled Trial Registry Entries and Content of Reports in Surgery Journals
Rosenthal, R., & Dwan, K. M. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318283cf7f · Cited by 49
Dissecting Effects of Complex Mixtures
Thomas, D. C., Witte, J. S., & Greenland, S. (2007) · Epidemiology · doi:10.1097/01.ede.0000254682.47697.70 · Cited by 52
FDA Responds to Institute of Medicine Drug Safety Recommendations—In Part
Psaty, B. M., & Charo, R. A. (2007) · JAMA · doi:10.1001/jama.297.17.1917 · Cited by 48
Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
Bello, A. E., & Holt, R. J. (2014) · Drug Safety · doi:10.1007/s40264-014-0207-2 · Cited by 45
Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
Schmidt, M., Lamberts, M., Olsen, A. S., Fosbøl, E. L., Niessner, A., Tamargo, J. L., Rosano, G. M. C., Agewall, S., Kaski, J. C., Kjeldsen, K. P., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv054 · Cited by 46
Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.
Brezis, M. (2008) · PubMed · Cited by 39
Lapses at the New England Journal of Medicine
Smith, R. W. (2006) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.99.8.380 · Cited by 48
Unpublished data can be of value in systematic reviews of adverse effects: methodological overview
Golder, S., Loke, Y. K., & Bland, M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.02.009 · Cited by 35
Clinical Trial Investigators and Their Prescribing Patterns
Psaty, B. M., & Rennie, D. (2006) · JAMA · doi:10.1001/jama.295.23.2787 · Cited by 30
Australasian College of Sports Physicians—position statement: the place of mesenchymal stem/stromal cell therapies in sport and exercise medicine
Osborne, H., Anderson, L. C., Burt, P., Young, M. A., & GERRARD, D. F. (2015) · British Journal of Sports Medicine · doi:10.1136/bjsports-2015-095711 · Cited by 29
Access to Safety Data — Stockholders versus Prescribers
Pfeffer, M. A., & Bowler, M. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1104699 · Cited by 29
Cyclooxygenase-2 inhibitors and cardiovascular risk
Solomon, S. D. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000245740.85829.4f · Cited by 27
U.S. Chamber of Commerce Liability Survey: Inaccurate, Unfair, and Bad for Business
Eisenberg, T. A. (2009) · Journal of Empirical Legal Studies · doi:10.1111/j.1740-1461.2009.01155.x · Cited by 25
Conflicts of Interest in Health Care: Who Guards the Guardians?
EPSTEIN, R. A. (2007) · Perspectives in biology and medicine · doi:10.1353/pbm.2007.0002 · Cited by 22
Ethical Considerations in the Interpretation and Communication of Clinical Trial Results
Coultas, D. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-007gc · Cited by 19
Off-Label Drug Use and Promotion: Balancing Public Health Goals and Commercial Speech
Kesselheim, A. S. (2011) · American Journal of Law & Medicine · doi:10.1177/009885881103700202 · Cited by 21
Safeguarding good scientific practice in Europe
Bosch, X. (2010) · EMBO Reports · doi:10.1038/embor.2010.32 · Cited by 20
“Putting Patients First”: Systematically Distorted Communication and Merck's Marketing of Vioxx
Lyon, A. R. (2007) · Journal of Applied Communication Research · doi:10.1080/00909880701611052 · Cited by 20
In‐basket Validity: A systematic review
Whetzel, D. L., Rotenberry, P. F., & McDaniel, M. A. (2014) · International Journal of Selection and Assessment · doi:10.1111/ijsa.12057 · Cited by 19
Litigation-Generated Science: Why Should We Care?
Boden, L. I., & Ozonoff, D. M. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.9987 · Cited by 19
Commentary: On 'Quality in epidemiological research: should we be submitting papers before we have the results and submitting more hypothesis generating research?'
Greenland, S. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym174 · Cited by 18
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events
Zhang, J., Ding, E. L., & Song, Y. (2017) · Cited by 15
Correction: Lung Transplantation and Survival in Children with Cystic Fibrosis
Liou, T. G., Adler, F. R., Cahill, B. C., & Cox, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc086289 · Cited by 15
Data availability for industry sponsored trials: what should medical journals require?
Steinbrook, R., & Kassirer, J. P. (2010) · BMJ · doi:10.1136/bmj.c5391 · Cited by 14
The Future of Conflicts of Interest: A Call for Professional Standards
Lo, B. (2012) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2012.00677.x · Cited by 13
Better Regulation of Industry-Sponsored Clinical Trials is Long Overdue
Wynia, M. K., & Boren, D. (2009) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2009.00402.x · Cited by 15
Statins and Adverse Cardiovascular Events in Moderate‐Risk Females: A Statistical and Legal Analysis with Implications for FDA Preemption Claims
Eisenberg, T. A., & Wells, M. T. (2008) · Journal of Empirical Legal Studies · doi:10.1111/j.1740-1461.2008.00132.x · Cited by 13
Commercial funding and estimated intervention effects in randomized clinical trials: Systematic review of meta‐epidemiological studies
Nejstgaard, C. H., Laursen, D. R. T., Lundh, A., & Hróbjartsson, A. (2022) · Research Synthesis Methods · doi:10.1002/jrsm.1611 · Cited by 12
What Your Doctor Should Know about Statistics (but Perhaps Doesn't…)
Switzer, S. S., & Horton, N. J. (2007) · CHANCE · doi:10.1080/09332480.2007.10722826 · Cited by 11
Australasian College of Sports Physicians—Position Statement
Osborne, H., Anderson, L. C., Burt, P., Young, M. A., & GERRARD, D. F. (2016) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000298 · Cited by 8
Race Differences in Personality: An Evaluation of Moderators and Publication Bias
Tate, B. W., & Mcdaniel, M. A. (2014) · Cited by 8
Science at the Crossroads: Fact or Fiction?
Goldberg, D. (2010) · Journal of Medical Biochemistry · doi:10.2478/v10011-011-0004-8 · Cited by 7
Complicity theory: an explanation for the `coxib problem'?
Dieppe, P. A. (2006) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.99.6.273 · Cited by 7
The Imperative of Ethical Communication Standards in an Era of Commercialized Medicine
Lyon, A. R., & Mirivel, J. C. (2010) · Management Communication Quarterly · doi:10.1177/0893318910370272 · Cited by 6
Long-Acting Broncho-Dilators: Time for a Re-think
Vassiliou, V. S., & Zipitis, C. S. (2006) · Journal of the Royal Society of Medicine · doi:10.1177/014107680609900803 · Cited by 6
Safe Drugs Versus Innovative Drugs (Can We Have Both?)
Raposo, V. L. (2019) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.041 · Cited by 6
DO PHARMACEUTICAL COMPANIES SELECTIVELY REPORT CLINICAL TRIAL DATA
Ahmer, S., Haider, I., Anderson, D., & Arya, P. (2006) · Cited by 5
Bias in research and conflict of interest: why should we care?
Dietz, H. P. (2006) · International Urogynecology Journal · doi:10.1007/s00192-006-0236-1 · Cited by 5
Conflicts of Interest and Disclosures in Publications
Camilleri, M., Dubnansky, E. C., & Rustgi, A. K. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.031 · Cited by 5
Toward a Philosophy of Error in Science
Allchin, D. (2025) · doi:10.1093/9780197827703.001.0001 · Cited by 4
When More Is Less: Overuse of Medical Services Harms Patients
Brownlee, S., Cassel, C. K., & Saini, V. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0407-5_1 · Cited by 4
Dealing With Unanticipated Mortality in a Large Randomized Clinical Trial of Topical Tretinoin
Schilling, L. M., & Dellavalle, R. P. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2008.520 · Cited by 4
Inconsistencies in Cardiovascular Data from COX-2 Inhibitor Trials–is it a Class Effect?
Weatherall, M., Aldington, S., Caldwell, B., & Beasley, R. (2006) · Journal of the Royal Society of Medicine · doi:10.1177/014107680609900604 · Cited by 4
Conflicts of Interest and Disclosures in Publications
Camilleri, M., Dubnansky, E. C., & Rustgi, A. K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.052 · Cited by 3
A fraude acadêmica hoje: as causas sociais e as respostas institucionais
Ávila, A. P. O. (2015) · REVISTA QUAESTIO IURIS · doi:10.12957/rqi.2015.20927 · Cited by 3
Detecting Safety Issues in Clinical Trials
Heeley, E. L. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-8818-1_5 · Cited by 3
Complicity Theory: An Explanation for the ‘Coxib Problem’?
Dieppe, P. A. (2006) · Journal of the Royal Society of Medicine · doi:10.1177/014107680609900603 · Cited by 3
Risiken und Nebenwirkungen von Arzneimitteln
Otte, A., Siskou, M., Lieber, D., Barsch, M., Konur, A., & Matzke, O. (2009) · Cited by 2
Deaths in trials should always be reported
Schroll, J. B. (2013) · BMJ · doi:10.1136/bmj.f4219 · Cited by 2
A Pharmacoepidemiological Network Model for Drug Safety Surveillance
Reis, B. Y., Olson, K. L., Tian, L., Bohn, R. L., Brownstein, J. S., Park, P. J., Cziraky, M. J., Wilson, M. D., & Mandl, K. D. (2012) · Drug Safety · doi:10.2165/11596610-000000000-00000 · Cited by 2
Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials
Criner, G. J. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-012gc · Cited by 2
An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible
Viereck, C., & Boudes, P. F. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.03.010 · Cited by 2
Pharmaceutical Promotion and First Amendment Rights
Troy, D. E., & Gottlieb, S. L. (2008) · New England Journal of Medicine · doi:10.1056/nejmc081122 · Cited by 2
How to Tell the Truth with Statistics: The Case for Accountable Data Analyses in Team-based Science.
Gelfond, J., Klugman, C. M., Welty, L. J., Heitman, E., Louden, C., & Pollock, B. H. (2014) · PubMed · Cited by 1
Tools for Assessment of Cardiovascular Tests and Therapies
Antman, E. M., Califf, R. M., & Kupersmith, J. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50007-3 · Cited by 1
Archiving Records and Materials
Werther, W., & Meinert, C. L. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_62 · Cited by 1
Requiem for international medical graduates
Natarajan, A. (2006) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.99.6.272 · Cited by 1
Opprobrium or opportunity?
Glick, M. (2006) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2006.0063 · Cited by 1
Evidence based medicine? Access to information & medicines regulation in New Zealand
Hill, A. (2013) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17006779.v1
Pharmaceutical Product Liabilities: A Review of Current Status and Future Trends
Boudes, P. F. (2009) · Drug Information Journal · doi:10.1177/009286150904300303
The US requirement to deposit trial data within a year is unworkable
Meinert, C. L. (2013) · BMJ · doi:10.1136/bmj.f6449
A BITTER PILL TO SWALLOW: CANADIAN DRUG REGULATION
Taylor, M. D. (2010) · eYLS (Yale Law School)
Conflicts of interest in biomedical publishing
Lundh, A. (2012)
Dealing with Scientific Misconduct in the Future ROLE OF EDITORS AND JOURNALS IN DETECTING AND PREVENTING SCIENTIFIC MISCONDUCT: STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS
Marušić, A., Katavić, V., & Marušić, M. (2007)
Epistemologga de la Medicina: CCmo saben los mmdicos que lo que saben es verdadero? El saber mmdico en la era del saber inducido por la industria farmaccutica: El caso Vioxx (Medicine's Epistemology: How Do Doctors Know What They Know is True? The Medical Knowledge in the Era of Big Pharma-Induced Knowledge: The Vioxx Case)Preprint
Ponce, M. F. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3119644
Archiving Records and Materials
Werther, W., & Meinert, C. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-52677-5_62-1
Chemical Regulation
Resnik, D. B. (2021) · The International Library of Bioethics · doi:10.1007/978-3-030-70791-0_6
Evidence based medicine? Access to information & medicines regulation in New Zealand
Hill, A. L. (2013) · doi:10.26686/wgtn.17006779
Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors
Hazlewood, G. S. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead388
Conceptual Errors
Allchin, D. (2025) · Oxford University Press eBooks · doi:10.1093/9780197827703.003.0003
List of Figures
Allchin, D. (2025) · Oxford University Press eBooks · doi:10.1093/9780197827703.002.0005
Error Itself
Allchin, D. (2025) · Oxford University Press eBooks · doi:10.1093/9780197827703.003.0001
Observational Errors
Allchin, D. (2025) · Oxford University Press eBooks · doi:10.1093/9780197827703.003.0002

Authors: Curfman, G. D., Morrissey, S., & Drazen, J. M.
ORCID: Curfman, Gregory D.
Morrissey, Stephen
Drazen, Jeffrey M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-03-16
Volume: 354
Issue: 11
Pages: 1193-1193
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejme068054
OpenAlex: W1998613929
Cited by: 109
References: 4
Citations by year: 2025: 14 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 6 · 2012: 6
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Topics: Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: rofecoxib, VIGOR trial, cardiovascular adverse events, drug safety, publication integrity, expression of concern
MeSH terms: Arthritis, Rheumatoid, Cardiovascular Diseases, Gastrointestinal Diseases, Humans, Lactones, Myocardial Infarction, Naproxen, Research Design, Sulfones, Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Expression of Concern Reaffirmed

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks